Artificial Tears Study in Mild to Moderate Dry Eye Patients

The mean change in the subjective comfort score from baseline of the test group is at least 2.0 units less than that of the control group.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Dry Eye Conjunctival Diseases Dry Eye Syndromes Eye Diseases Lacrimal Apparatus Diseases Xerophthalmia

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Mild to moderate dry eye
over 18

Exclusion criteria

No concurrent ocular disease or meds

Treatment and study plan

(9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400

Drug

Drops

Systane

Drug

Drops

Primary outcomes

Subjective ocular comfort

Time frame: 1 Month

Secondary outcomes

Vision quality

Time frame: 1 Month

Sponsors and collaborators

Lead sponsor

Abbott Medical Optics

Industry

Registry information

Important dates

Study start: 2007
Study completion: 2007
First posted: Feb 6, 2008
Registry last updated: Feb 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed